In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents

ABSTRACT We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.

Download Full-text

In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.46.6.1723-1727.2002 ◽

2002 ◽

Vol 46 (6) ◽

pp. 1723-1727 ◽

Cited By ~ 153

Author(s):

M. A. Pfaller ◽

S. A. Messer ◽

R. J. Hollis ◽

R. N. Jones ◽

D. J. Diekema

Keyword(s):

Candida Albicans ◽

Amphotericin B ◽

Antifungal Agents ◽

Vitro Activity ◽

Clinical Isolates ◽

In Vitro Activity ◽

Candida Spp ◽

Medical Centers ◽

Dose Dependent

ABSTRACT The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin B, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of Candida spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all Candida spp. (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.25 μg/ml; 98% of MICs were ≤1 μg/ml); however, a decrease in the activities of both of these agents was noted among isolates that were susceptible-dose dependent (fluconazole MIC, 16 to 32 μg/ml) and resistant (MIC, ≥ 64 μg/ml) to fluconazole. Candida albicans was the most susceptible species (MIC90 of both ravuconazole and voriconazole, 0.03 μg/ml), and C. glabrata was the least susceptible species (MIC90, 1 to 2 μg/ml). Ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazole against all Candida spp. and were the only agents with good in vitro activity against C. krusei. These results provide further evidence for the spectrum and potency of ravuconazole and voriconazole against a large and geographically diverse collection of Candida spp.

Download Full-text

In Vitro Activities of Approved and Investigational Antifungal Agents against 44 Clinical Isolates of Basidiomycetous Fungi

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.45.2.633-635.2001 ◽

2001 ◽

Vol 45 (2) ◽

pp. 633-635 ◽

Cited By ~ 53

Author(s):

Gloria M. González ◽

Deanna A. Sutton ◽

Elizabeth Thompson ◽

Rolando Tijerina ◽

Michael G. Rinaldi

Keyword(s):

Amphotericin B ◽

Antifungal Agents ◽

Schizophyllum Commune ◽

Vitro Activity ◽

Clinical Isolates ◽

In Vitro Activity ◽

Bjerkandera Adusta

ABSTRACT The in vitro activity of amphotericin B, fluconazole, flucytosine, itraconazole, voriconazole, and posaconazole was evaluated against 44 clinical isolates of filamentous basidiomycetous fungi. No statistically significant differences were noted betweenSchizophyllum commune (n = 5),Coprinus species (n = 8),Bjerkandera adusta (n = 14), and sterile, uncharacterized basidiomycetes (n = 17).

Download Full-text

In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkaa351 ◽

2020 ◽

Vol 75 (12) ◽

pp. 3582-3585

Author(s):

Olga Rivero-Menendez ◽

Manuel Cuenca-Estrella ◽

Ana Alastruey-Izquierdo

Keyword(s):

Amphotericin B ◽

Susceptibility Testing ◽

Antifungal Susceptibility ◽

Vitro Activity ◽

Clinical Isolates ◽

Scedosporium Apiospermum ◽

In Vitro Activity ◽

Scedosporium Dehoogii ◽

Scedosporium Species

Abstract Objectives To evaluate the in vitro activity of olorofim, a new broad-spectrum antifungal with a novel mechanism of action, against a collection of 123 Spanish clinical isolates belonging to five Scedosporium species and Lomentospora prolificans. Methods The activity of olorofim against Scedosporium apiospermum (n = 30), Scedosporium boydii (n = 30), Scedosporium ellipsoideum (n = 10), Scedosporium aurantiacum (n = 20), Scedosporium dehoogii (n = 3) and Lomentospora prolificans (n = 30) was compared with that of amphotericin B, voriconazole, isavuconazole and micafungin by performing EUCAST and CLSI reference methods for antifungal susceptibility testing. Results Amphotericin B and isavuconazole showed MICs ≥2 mg/L for all the species evaluated and voriconazole was moderately active (GM, MIC50 and MIC90 values ≤2 mg/L) against all of them except L. prolificans. Micafungin was effective against S. apiospermum complex strains, but exhibited elevated MECs for S. dehoogii and S. aurantiacum. Olorofim showed low MICs for all the Scedosporium strains tested (GM values were lower than 0.130 and 0.339 by the EUCAST method and the CLSI method, respectively, for all of the species), including those belonging to the MDR species L. prolificans, for which GM values were 0.115 and 0.225 mg/L by the EUCAST method and the CLSI method, respectively, while the GMs for the rest of the antifungals evaluated were higher than 3.732 mg/L using both methodologies. Conclusions Olorofim displayed promising in vitro activity against the Scedosporium and L. prolificans strains tested, some of which have reduced susceptibility to the antifungals that are currently in use.

Download Full-text

Comparison of In Vitro Activity of Liposomal Nystatin againstAspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.43.5.1264 ◽

1999 ◽

Vol 43 (5) ◽

pp. 1264-1266 ◽

Cited By ~ 37

Author(s):

Karen L. Oakley ◽

Caroline B. Moore ◽

David W. Denning

Keyword(s):

Amphotericin B ◽

Aspergillus Terreus ◽

Antifungal Agents ◽

Geometric Mean ◽

Colloidal Dispersion ◽

Vitro Activity ◽

In Vitro Activity ◽

Lipid Complex

ABSTRACT We compared the in vitro activity of liposomal nystatin (Nyotran) with those of other antifungal agents against 60Aspergillus isolates. Twelve isolates were itraconazole resistant. For all isolates, geometric mean (GM) MICs (micrograms per milliliter) were 2.30 for liposomal nystatin, 0.58 for itraconazole, 0.86 for amphotericin B (AB) deoxycholate, 9.51 for nystatin, 2.07 for liposomal AB, 2.57 for AB lipid complex, and 0.86 for AB colloidal dispersion. Aspergillus terreus (GM, 8.72 μg/ml; range, 8 to 16 μg/ml) was significantly less susceptible to all of the polyene drugs than all other species (P = 0.0001).

Download Full-text

Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/42.4.531 ◽

1998 ◽

Vol 42 (4) ◽

pp. 531-533 ◽

Cited By ~ 67

Author(s):

M. Cuenca-Estrella ◽

J. L. Rodriguez-Tudela ◽

E. Mellado ◽

J. V. Martinez-Suarez ◽

A. Monzon

Keyword(s):

Aspergillus Fumigatus ◽

Amphotericin B ◽

Vitro Activity ◽

Clinical Isolates ◽

In Vitro Activity

Download Full-text

In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.40.9.2229 ◽

1996 ◽

Vol 40 (9) ◽

pp. 2229-2231 ◽

Cited By ~ 9

Author(s):

H M Wardle ◽

D Law ◽

D W Denning

Keyword(s):

High Resolution ◽

Amphotericin B ◽

Clinical Studies ◽

Antifungal Agents ◽

Vitro Activity ◽

In Vitro Activity ◽

Candida Spp ◽

New Class ◽

Microdilution Method

We compared the in vitro activity of BMS-181184, the first compound of a new class of antifungal agents, the pradimicins, with those of fluconazole and amphotericin B against 64 clinical isolates of Candida species. MICs were determined by a microdilution method with high resolution medium for BMS-181184 and fluconazole and antibiotic medium no. 3 with 2% glucose for amphotericin B. MICs of BMS-181184 for all yeasts were in the range of 0.78 to 12.5 micrograms/ml. BMS-181184 was active against isolates resistant to other antifungal agents, consistent with a novel mode of action. Minimum fungicidal concentrations for 16 isolates showed that BMS-181184 was fungicidal. Clinical studies are now required to confirm its activity.

Download Full-text